{
  "legislationId": "119_HR_7902",
  "lastUpdate": "2026-04-22T11:16:57.422Z",
  "history": [
    {
      "timestamp": "2026-04-22T11:16:57.422Z",
      "source_url": "https://www.congress.gov/119/bills/hr7902/BILLS-119hr7902ih.htm",
      "model": "gemini-flash-lite-latest",
      "prompt_sent": "\nROLE: Fact Checker.\nZADANIE: Porównaj SOURCE (oryginał) i SUMMARY (streszczenie przygotowane przez inne AI).\n\nTwoim celem jest wykrycie \"ZMYŚLONYCH KONKRETÓW\" (Fabricated Entities) w SUMMARY.\n\nSOURCE:\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 7902 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 7902 To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES March 12, 2026 Mrs. Harshbarger introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Safeguarding Women from Chemical Abortion Act''. SEC. 2. WITHDRAWAL OF APPROVAL OF THE DRUG MIFEPRISTONE FOR TERMINATION OF PREGNANCY. Effective upon the expiration of 14 days after the date of the enactment of this Act: (1) Approval of an application submitted under subsection (b) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for the drug mifepristone (marketed as Mifeprex, and also known as RU-486) with an indication for the termination of intrauterine pregnancy, and of any application submitted under subsection (j) of such section for a drug with the same indication and for which mifepristone is the reference drug, is deemed to have been withdrawn under subsection (e) of such section. (2) For purposes of sections 301(d) and 304 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(d); 334), the introduction or delivery for introduction of a drug, the approval of which has been withdrawn as described in paragraph (1), into interstate commerce shall be considered a violation of section 505 of such Act (21 U.S.C. 355). (3) The drug mifepristone shall be considered misbranded for purposes of sections 301 and 304 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331; 334) if the drug bears labeling providing that the drug may be used for the termination of intrauterine pregnancy or that the drug may be used in conjunction with another drug for the termination of intrauterine pregnancy. SEC. 3. FEDERAL TORT FOR HARM TO WOMEN CAUSED BY CHEMICAL ABORTION DRUGS. (a) Definitions.--In this section: (1) Covered entity.--The term ``covered entity'' means a person that manufactures a covered medication for introduction into interstate commerce. (2) Covered medication.--The term ``covered medication'' means the drug mifepristone (marketed as Mifeprex, and also known as RU-486), with an indication for the termination of intrauterine pregnancy, approved pursuant to an application submitted under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355). (b) Liability.--A covered entity shall be liable in accordance with this section to any individual who suffers bodily injury or harm to mental health (including any physical, psychological, emotional, or physiological harm) that is attributable, in whole or in part, to the individual's use of a covered medication manufactured by a covered entity. (c) Private Right of Action.--An individual who suffers bodily injury or harm to mental health that is attributable, in whole or in part, to the individual's use of a covered medication as described in subsection (b) may bring a civil action against the covered entity in an appropriate district court of the United States or a State court of competent jurisdiction for-- (1) compensatory damages; (2) punitive damages; and (3) attorney's fees and costs. (d) Rules of Construction.--Nothing in this section shall be construed to preempt any State law that makes available any other remedy to an individual described in subsection (b). (e) Effective Date.--This section shall take effect on the date that is 90 days after the date of enactment of this Act. SEC. 4. RULE OF CONSTRUCTION. Nothing in this Act shall be construed to affect any provision of section 1461 of title 18, United States Code. <all>\n\nSUMMARY TO EVALUATE:\nTitle: Ban on mifepristone for abortion and new federal lawsuits against manufacturers\nSummary: This bill withdraws federal approval for the drug mifepristone when used for abortion. It also establishes a new right for individuals to sue manufacturers for physical or mental harm caused by the drug.\nKey Points: Withdrawal of FDA approval for mifepristone for pregnancy termination within 14 days of enactment., Ban on the interstate sale and distribution of the drug for abortion purposes., New federal right to sue manufacturers for physical, psychological, or emotional injuries., Victims can seek compensatory damages, punitive damages, and recovery of legal fees., The drug will be considered misbranded if labeled for use in terminating pregnancies.\n\nZASADY OCENY:\n1. Sprawdź wszystkie LICZBY, DATY i KWOTY w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n2. Sprawdź wszystkie NAZWISKA, ORGANIZACJE i MIEJSCA w SUMMARY. Jeśli którejś brakuje w SOURCE -> is_valid: false.\n3. Sprawdź wszystkie konkretne DZIAŁANIA PRAWNE . Jeśli tego mechanizmu nie ma w SOURCE -> is_valid: false.\n\nWAŻNE: Abstrakcyjne pojęcia (np. \"transparentność\", \"zaufanie\") są dozwolone jako wnioski.\n\nOUTPUT (JSON):\n{\n  \"is_valid\": true/false,\n  \"issue\": \"fabricated_entity\" / \"contradiction\" / \"none\"\n}\n\nWYMAGANIA FORMATOWANIA:\n1. Odpowiedz WYŁĄCZNIE surowym obiektem JSON.\n2. NIE używaj bloków kodu Markdown.\n3. NIE dodawaj żadnych wstępów ani wyjaśnień przed ani po JSONie.\n4. JSON musi być poprawny i gotowy do parsowania.\n\n",
      "ai_response_raw": "{\n  \"is_valid\": true,\n  \"issue\": \"none\"\n}"
    },
    {
      "timestamp": "2026-04-22T11:12:46.551Z",
      "source_url": "https://www.congress.gov/119/bills/hr7902/BILLS-119hr7902ih.htm",
      "model": "gemini-flash-latest",
      "prompt_sent": "\nJesteś ekspertem od prawa Stanów Zjednoczonych, który ma za zadanie analizować dokumenty ustaw, uchwał oraz innych dokumentów legislacyjnych, a następnie przygotowywać z nich informacje w przystępny sposób dla obywateli. Twoim celem jest przedstawienie informacji tak, aby obywatele mogli sami ocenić wpływ legislacji na ich życie, nawet bez posiadania specjalistycznej wiedzy legislacyjnej. Skup się na faktach i obiektywnych skutkach wprowadzanych zmian, unikając wartościowania i osobistych opinii. Wszelki żargon prawny jest zabroniony. Prezentuj informacje w jasny, zwięzły i angażujący sposób, tak aby były zrozumiałe dla osoby bez wykształcenia prawniczego. Unikaj długich, złożonych zdań. Zamiast pisać \"projekt ma na celu nowelizację kodeksu podatkowego...\", napisz \"Zmiany w podatkach: nowe ulgi i obowiązki dla...\". Kontynuuj swoją pracę, dopóki nie rozwiążesz swojego zadania. Jeśli nie masz pewności co do generowanej treści, przeanalizuj dokument ponownie – nie zgaduj. Rozplanuj dobrze swoje zadanie przed przystąpieniem do niego. W podsumowaniu i kluczowych punktach, jeśli to możliwe i uzasadnione, podkreśl, jakie konkretne korzyści lub skutki (pozytywne lub negatywne) wprowadza ustawa dla życia codziennego obywateli, ich praw i obowiązków, finansów osobistych, bezpieczeństwa i innych ważnych kwestii (np. kategorycznych zakazów i nakazów czy najważniejszych konkretnych alokacji finansowych i terytorialnych).\n\nTwoja odpowiedź MUSI być w formacie JSON - i zawierać następujące klucze.\nZanim zwrócisz odpowiedź, dokładnie zweryfikuj, czy cała struktura JSON jest w 100% poprawna, włącznie ze wszystkimi przecinkami, nawiasami klamrowymi, kwadratowymi oraz cudzysłowami. Błędny JSON jest nieakceptowalny i uniemożliwi przetworzenie Twojej pracy.\n\nPrzeanalizuj dokładnie poniższy tekst dokumentu prawnego. To jest treść, na podstawie której masz wygenerować podsumowanie i kluczowe punkty:\n--- POCZĄTEK DOKUMENTU ---\n[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 7902 Introduced in House (IH)] <DOC> 119th CONGRESS 2d Session H. R. 7902 To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES March 12, 2026 Mrs. Harshbarger introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned _______________________________________________________________________ A BILL To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Safeguarding Women from Chemical Abortion Act''. SEC. 2. WITHDRAWAL OF APPROVAL OF THE DRUG MIFEPRISTONE FOR TERMINATION OF PREGNANCY. Effective upon the expiration of 14 days after the date of the enactment of this Act: (1) Approval of an application submitted under subsection (b) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) for the drug mifepristone (marketed as Mifeprex, and also known as RU-486) with an indication for the termination of intrauterine pregnancy, and of any application submitted under subsection (j) of such section for a drug with the same indication and for which mifepristone is the reference drug, is deemed to have been withdrawn under subsection (e) of such section. (2) For purposes of sections 301(d) and 304 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(d); 334), the introduction or delivery for introduction of a drug, the approval of which has been withdrawn as described in paragraph (1), into interstate commerce shall be considered a violation of section 505 of such Act (21 U.S.C. 355). (3) The drug mifepristone shall be considered misbranded for purposes of sections 301 and 304 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331; 334) if the drug bears labeling providing that the drug may be used for the termination of intrauterine pregnancy or that the drug may be used in conjunction with another drug for the termination of intrauterine pregnancy. SEC. 3. FEDERAL TORT FOR HARM TO WOMEN CAUSED BY CHEMICAL ABORTION DRUGS. (a) Definitions.--In this section: (1) Covered entity.--The term ``covered entity'' means a person that manufactures a covered medication for introduction into interstate commerce. (2) Covered medication.--The term ``covered medication'' means the drug mifepristone (marketed as Mifeprex, and also known as RU-486), with an indication for the termination of intrauterine pregnancy, approved pursuant to an application submitted under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355). (b) Liability.--A covered entity shall be liable in accordance with this section to any individual who suffers bodily injury or harm to mental health (including any physical, psychological, emotional, or physiological harm) that is attributable, in whole or in part, to the individual's use of a covered medication manufactured by a covered entity. (c) Private Right of Action.--An individual who suffers bodily injury or harm to mental health that is attributable, in whole or in part, to the individual's use of a covered medication as described in subsection (b) may bring a civil action against the covered entity in an appropriate district court of the United States or a State court of competent jurisdiction for-- (1) compensatory damages; (2) punitive damages; and (3) attorney's fees and costs. (d) Rules of Construction.--Nothing in this section shall be construed to preempt any State law that makes available any other remedy to an individual described in subsection (b). (e) Effective Date.--This section shall take effect on the date that is 90 days after the date of enactment of this Act. SEC. 4. RULE OF CONSTRUCTION. Nothing in this Act shall be construed to affect any provision of section 1461 of title 18, United States Code. <all>\n--- KONIEC DOKUMENTU ---\n\nPAMIĘTAJ: Twoja odpowiedź MUSI być wyłącznie poprawnym obiektem JSON. Nie dodawaj żadnych dodatkowych znaków, komentarzy ani tekstu przed znacznikiem '{' ani po znaczniku '}'. Cała odpowiedź musi być parsowalna jako JSON.\nNa podstawie POWYŻSZEGO dokumentu, wypełnij poniższą strukturę JSON:\nOto struktura JSON, której oczekuję (wypełnij ją treścią):\n{\n  \"pl_ai_title\": \"Nowy, krótki tytuł dla aktu prawnego po polsku, oddający sedno wprowadzanych zmian (np. maksymalnie 10-12 słów).\",\n  \"pl_summary\": \"2-3 zdania zwięzłego podsumowania treści aktu prawnego po polsku, napisane z perspektywy wpływu na życie codzienne obywateli.\",\n  \"pl_key_points\": [\n    \"Pierwszy krótki punkt po polsku dotyczący najważniejszych wprowadzanych rozwiązań lub zmian.\",\n    \"Drugi krótki punkt po polsku...\"\n  ],\n  \"eng_ai_title\": \"A new, short title for the legal act in English, capturing the essence of the changes (e.g., max 10-12 words).\",\n  \"eng_summary\": \"2-3 sentences summarizing the legal act in English, from the perspective of its impact on citizens' daily lives.\",\n  \"eng_key_points\": [\n    \"First short bullet point in English regarding the most important solutions or changes being introduced.\",\n    \"Second short bullet point in English...\"\n  ],\n  \"de_ai_title\": \"Ein neuer, kurzer Titel für das Rechtsdokument auf Deutsch, der den Kern der Änderungen erfasst (z.B. max. 10-12 Wörter).\",\n  \"de_summary\": \"2-3 Sätze Zusammenfassung des Rechtsdokuments auf Deutsch, aus der Perspektive seiner Auswirkungen auf das tägliche Leben der Bürger.\",\n  \"de_key_points\": [\n    \"Erster kurzer Stichpunkt auf Deutsch zu den wichtigsten eingeführten Lösungen oder Änderungen.\",\n    \"Zweiter kurzer Stichpunkt auf Deutsch...\"\n  ],\n  \"fr_ai_title\": \"Un nouveau titre court pour l'acte juridique en français, saisissant l'essence des changements (par exemple, 10-12 mots maximum).\",\n  \"fr_summary\": \"Résumé de 2-3 phrases de l'acte juridique en français, du point de vue de son impact sur la vie quotidienne des citoyens.\",\n  \"fr_key_points\": [\n    \"Premier court point en français concernant les solutions ou changements les plus importants introduits.\",\n    \"Deuxième court point en français...\"\n  ],\n  \"es_ai_title\": \"Un nuevo título breve para el acto jurídico en español, que recoja la esencia de los cambios (por ejemplo, máximo 10-12 palabras).\",\n  \"es_summary\": \"Resumen de 2-3 frases del acto jurídico en español, desde la perspectiva de su impacto en la vida cotidiana de los ciudadanos.\",\n  \"es_key_points\": [\n    \"Primer punto breve en español sobre las soluciones o cambios más importantes que se introducen.\",\n    \"Segundo punto breve en español...\"\n  ],\n  \"it_ai_title\": \"Un nuovo titolo breve per l'atto giuridico in italiano, che colga l'essenza delle modifiche (ad es. massimo 10-12 parole).\",\n  \"it_summary\": \"Riepilogo di 2-3 frasi dell'atto giuridico in italiano, dal punto di vista del suo impatto sulla vita quotidiana dei cittadini.\",\n  \"it_key_points\": [\n    \"Primo breve punto in italiano riguardante le soluzioni o le modifiche più importanti introdotte.\",\n    \"Secondo breve punto in italiano...\"\n  ],\n  \"nl_ai_title\": \"Een nieuwe, korte titel voor de rechtshandeling in het Nederlands, die de essentie van de wijzigingen weergeeft (bijv. max. 10-12 woorden).\",\n  \"nl_summary\": \"Samenvatting van 2-3 zinnen van de rechtshandeling in het Nederlands, vanuit het perspectief van de impact op het dagelijks leven van burgers.\",\n  \"nl_key_points\": [\n    \"Eerste korte punt in het Nederlands betreffende de belangrijkste geïntroduceerde oplossingen of wijzigingen.\",\n    \"Tweede korte punt in het Nederlands...\"\n  ],\n  \"pt_ai_title\": \"Um novo título curto para o ato jurídico em português, capturando a essência das mudanças (por exemplo, máx. 10-12 palavras).\",\n  \"pt_summary\": \"Resumo de 2-3 frases do ato jurídico em português, na perspetiva do seu impacto na vida quotidiana dos cidadãos.\",\n  \"pt_key_points\": [\n    \"Primeiro ponto curto em português sobre as soluções ou alterações mais importantes introduzidas.\",\n    \"Segundo ponto curto em português...\"\n  ],\n  \"category\": [\"Categorize the document into one category by default, based on the field it primarily concerns. Choose up to 3 if the document also touches upon SIGNIFICANT issues from other categories. You MUST select categories ONLY from the following list: Health, Education, Family, Taxes, Labor, Security, Environment, Courts and Law, Transport, Benefits, Real Estate, Media and Culture, Local Government, Migration, Agriculture, Public Investments, Informatization, Economy. If the document does not definitively fit any of these, you MUST use \"Other\". If you use \"Other\", it should be the ONLY category selected. Do NOT invent new categories. The response must be an array of strings, e.g., [\"Taxes\", \"Family\"].\"]\n}\n\n",
      "ai_response_raw": "{\n  \"pl_ai_title\": \"Zakaz stosowania mifepristonu do aborcji i nowe prawo do odszkodowań od producentów\",\n  \"pl_summary\": \"Ustawa wycofuje federalną zgodę na sprzedaż leku mifepriston w celu przerywania ciąży. Wprowadza również możliwość pozywania producentów za wszelkie szkody fizyczne i psychiczne powstałe w wyniku zażycia tego leku.\",\n  \"pl_key_points\": [\n    \"Wycofanie zgody na stosowanie leku mifepriston do przerywania ciąży w ciągu 14 dni od wejścia ustawy w życie.\",\n    \"Uznanie transportu i sprzedaży leku w celach aborcyjnych między stanami za naruszenie prawa.\",\n    \"Możliwość pozywania producentów leku za szkody fizyczne, psychiczne i emocjonalne u pacjentek.\",\n    \"Prawo do ubiegania się o odszkodowania, zadośćuczynienie oraz zwrot kosztów prawnych w sądzie.\",\n    \"Uznanie leku za błędnie oznakowany, jeśli jego etykieta sugeruje użycie do przerywania ciąży.\"\n  ],\n  \"eng_ai_title\": \"Ban on mifepristone for abortion and new federal lawsuits against manufacturers\",\n  \"eng_summary\": \"This bill withdraws federal approval for the drug mifepristone when used for abortion. It also establishes a new right for individuals to sue manufacturers for physical or mental harm caused by the drug.\",\n  \"eng_key_points\": [\n    \"Withdrawal of FDA approval for mifepristone for pregnancy termination within 14 days of enactment.\",\n    \"Ban on the interstate sale and distribution of the drug for abortion purposes.\",\n    \"New federal right to sue manufacturers for physical, psychological, or emotional injuries.\",\n    \"Victims can seek compensatory damages, punitive damages, and recovery of legal fees.\",\n    \"The drug will be considered misbranded if labeled for use in terminating pregnancies.\"\n  ],\n  \"de_ai_title\": \"Verbot von Mifepriston für Abtreibungen und neue Haftungsregeln für Hersteller\",\n  \"de_summary\": \"Dieses Gesetz entzieht dem Medikament Mifepriston die Zulassung für Schwangerschaftsabbrüche. Zudem wird eine Haftung für Hersteller bei körperlichen oder psychischen Schäden eingeführt.\",\n  \"de_key_points\": [\n    \"Widerruf der Zulassung von Mifepriston zur Abtreibung innerhalb von 14 Tagen nach Inkrafttreten.\",\n    \"Verbot des zwischenstaatlichen Handels mit dem Medikament für Zwecke des Schwangerschaftsabbruchs.\",\n    \"Neues Klagerecht gegen Hersteller bei körperlichen, psychischen oder emotionalen Gesundheitsschäden.\",\n    \"Anspruch auf Schadenersatz, Strafschadenersatz und Erstattung von Anwaltskosten.\",\n    \"Einstufung des Medikaments als falsch etikettiert, wenn es Hinweise auf eine Verwendung zur Abtreibung enthält.\"\n  ],\n  \"fr_ai_title\": \"Interdiction de la mifépristone pour l'avortement et nouvelle responsabilité des fabricants\",\n  \"fr_summary\": \"Ce projet de loi retire l'autorisation de mise sur le marché de la mifépristone pour l'interruption de grossesse. Il permet également de poursuivre les fabricants en cas de dommages physiques ou mentaux.\",\n  \"fr_key_points\": [\n    \"Retrait de l'approbation de la mifépristone pour l'avortement sous 14 jours après l'adoption.\",\n    \"Interdiction du commerce inter-États du médicament pour cet usage spécifique.\",\n    \"Création d'un droit de recours civil contre les fabricants pour préjudice physique ou psychologique.\",\n    \"Possibilité d'obtenir des dommages-intérêts compensatoires, punitifs et le remboursement des frais d'avocat.\",\n    \"Le médicament sera considéré comme mal étiqueté s'il mentionne l'usage pour l'interruption de grossesse.\"\n  ],\n  \"es_ai_title\": \"Prohibición de la mifepristona para el aborto y nuevas responsabilidades legales\",\n  \"es_summary\": \"Esta ley retira la aprobación del medicamento mifepristona para la interrupción del embarazo. Además, permite demandar a los fabricantes por daños físicos o mentales causados por el fármaco.\",\n  \"es_key_points\": [\n    \"Retirada de la aprobación de la mifepristona para el aborto en un plazo de 14 días.\",\n    \"Prohibición de la venta y transporte interestatal del fármaco para fines abortivos.\",\n    \"Derecho a demandar a los fabricantes por daños físicos, psicológicos o emocionales.\",\n    \"Posibilidad de recibir indemnizaciones por daños y perjuicios, daños punitivos y costas legales.\",\n    \"El fármaco se considerará mal etiquetado si su etiqueta indica su uso para el aborto.\"\n  ],\n  \"it_ai_title\": \"Divieto di mifepristone per l'aborto e nuove norme sulla responsabilità civile\",\n  \"it_summary\": \"Questa legge revoca l'approvazione del farmaco mifepristone per l'interruzione di gravidanza. Introduce inoltre la possibilità di citare in giudizio i produttori per danni fisici o mentali.\",\n  \"it_key_points\": [\n    \"Revoca dell'approvazione del mifepristone per l'aborto entro 14 giorni dall'entrata in vigore.\",\n    \"Divieto di commercio interstatale del farmaco per scopi abortivi.\",\n    \"Diritto di intentare cause civili contro i produttori per danni alla salute fisica o psichica.\",\n    \"Possibilità di ottenere risarcimenti danni, danni punitivi e il rimborso delle spese legali.\",\n    \"Il farmaco sarà considerato etichettato impropriamente se riporta indicazioni per l'aborto.\"\n  ],\n  \"nl_ai_title\": \"Verbod op mifepriston voor abortus en nieuwe aansprakelijkheid voor fabrikanten\",\n  \"nl_summary\": \"Deze wet trekt de goedkeuring voor het medicijn mifepriston voor zwangerschapsafbreking in. Ook kunnen fabrikanten voortaan aansprakelijk worden gesteld voor lichamelijke of mentale schade.\",\n  \"nl_key_points\": [\n    \"Intrekking van de goedkeuring voor mifepriston voor abortus binnen 14 dagen na bekrachtiging.\",\n    \"Verbod op het vervoeren of verkopen van het middel tussen staten voor abortusdoeleinden.\",\n    \"Nieuw recht om fabrikanten aan te klagen voor fysieke, psychologische of emotionele schade.\",\n    \"Mogelijkheid tot schadevergoeding, punitieve schadevergoeding en vergoeding van juridische kosten.\",\n    \"Het medicijn wordt als verkeerd geëtiketteerd beschouwd als de verpakking gebruik voor abortus vermeldt.\"\n  ],\n  \"pt_ai_title\": \"Proibição da mifepristona para o aborto e novas regras de responsabilidade\",\n  \"pt_summary\": \"Esta lei retira a aprovação do medicamento mifepristona para a interrupção da gravidez. Estabelece também o direito de processar fabricantes por danos físicos ou mentais causados pelo uso do fármaco.\",\n  \"pt_key_points\": [\n    \"Retirada da aprovação da mifepristona para o aborto no prazo de 14 dias após a promulgação.\",\n    \"Proibição do comércio interestadual do medicamento para fins de interrupção de gravidez.\",\n    \"Direito de ação civil contra fabricantes por danos físicos, psicológicos ou emocionais.\",\n    \"Possibilidade de indemnizações compensatórias, punitivas e pagamento de honorários advocatícios.\",\n    \"O medicamento será considerado mal rotulado se a etiqueta indicar o uso para o aborto.\"\n  ],\n  \"category\": [\"Health\", \"Courts and Law\"]\n}"
    }
  ]
}